MAGE-A8 | ApexOnco - Clinical Trials news and analysis

x

“OncologyPipeline is my favorite CI tool”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Conferences Deals Trial results

17 September 2024

ESMO 2024 – Bristol abandonment overshadows Immatics

Conferences

22 July 2024

ESMO 2024 preview – Summit and BioNTech battle again

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Subscribe to MAGE-A8